NORTHLAND

NORTHLAND

Language

The company’s R&D project has once again been approved as a key national special project for the development of new drugs.

发布时间：2017-12-07

The application process for the 2017 projects under the major national science and technology special project for the creation of new drugs, led and organized by the National Health and Family Planning Commission and the Logistics Support Department of the Central Military Commission, was launched at the beginning of this year. After several rounds of review and evaluation, our company’s proposed project—“Clinical Study of a Class 1 New Drug for the Treatment of Myocardial Infarction: Recombinant Human Thymosin β4” (project number: 2017ZX09303009)—has been approved and received funding support.

23

2017-10

NORTHLAND Obtains Another Trademark Registration Certificate

发布时间：2017-10-23

On October 20, 2017, the company's trademark application for the word-and-graphic mark "NORTHLAND N N," which features both text and a graphic element, was approved and granted a Trademark Registration Certificate by the Trademark Office of the State Administration for Industry and Commerce. The approved goods/services categories (international classifications: 5; 10; 35; 42; 44) are valid from June 28, 2017, to June 27, 2027.

10

2017-10

Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection Granted Approval for Phase III Clinical Trials

发布时间：2017-10-10

Recently, Beijing Northland Biotechnology Co., Ltd. received the "Drug Clinical Trial Approval" (Approval No.: 2017L04713) approved and issued by the National Medical Products Administration, which authorizes the Phase III clinical trial of recombinant human hepatocyte growth factor naked plasmid injection for the indication of lower limb arterial ischemic disease.

11

2017-07

The Phase I clinical trial of recombinant human thymosin β4 for injection has officially commenced.

发布时间：2017-07-11

On July 10, 2017, the kickoff meeting for the Phase I clinical trial of "Recombinant Human Thymosin β4 for Injection" organized by Beijing Northland Biotechnology Co., Ltd. was successfully held at the Kyoto Xinyuan Hotel in Beijing.

22

2017-05

NORTHLAND Attends the 3rd BFC Medical and Healthcare Industry Business Development and Investment Cooperation Exchange Conference

发布时间：2017-05-22

From May 18 to 19, 2017, the 3rd BFC Healthcare Industry Business Development and Investment Cooperation Exchange Conference was held at the Grand Hyatt Shanghai. Our company was invited to participate in this BFC HealthCare Investment Cooperation Exchange Conference. At the conference, our company gave a focused presentation on the progress of our pipeline new drug projects, technology transfer activities, and our corporate development strategy, attracting widespread attention from attending investors and business partners. In addition, senior executives from our company engaged in one-on-one meetings with several well-known institutional investors and outstanding enterprises in the biopharmaceutical R&D sector, discussing topics such as our company’s development and future financing needs, as well as trends and the overall environment of domestic and international pharmaceutical markets. As a result, we established initial cooperative relationships and reached preliminary intentions for collaboration.

13

2017-01

NORTHLAND has been approved for a national-level key R&D special project.

发布时间：2017-01-13

Recently, the 2016 projects under the key special program "International Science and Technology Innovation Cooperation between Governments" of the National Key R&D Program were finalized. The project titled "Joint Research on an Integrated Sterilization Production Process for Eye Drop Preparations via Blow-Fill-Seal," jointly submitted by NORTHLAND and South Korea's Huons and recommended by the Beijing Municipal Science & Technology Commission, has been approved and funded under the key special program "International Science and Technology Innovation Cooperation between Governments" of the National Key R&D Program administered by the Ministry of Science and Technology.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy